Anbio Biotechnology develops and commercializes in-vitro diagnostic (IVD) products across platforms such as lateral-flow immunoassays, molecular assays, and other laboratory and point-of-care formats. The company targets decentralized, rapid testing for labs, clinics, wellness channels, and at-home use, aiming to make diagnostics more accessible and affordable. Its revenue base has been weighted toward infectious-disease rapid tests while it expands into broader clinical areas including oncology and cardiovascular applications.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 23.5 | — | 10 | — |
| 2023 | 6.7 | -71.5% | 2.3 | -77.5% |
| 2024 | 8.2 | 21.9% | 2.4 | 5.3% |
| 2025 | 8.7 | 5.6% | 6.4 | 169.9% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Aviat Networks, Inc. (AVNW), Solarius Capital Acquisition Corp. (SOCA), PAMT CORP (PAMT), Pyxis Oncology, Inc. (PYXS), Invest Green Acquisition Corporation (IGAC), Lifecore Biomedical, Inc. (LFCR)